Drugs and vaccines for COVID-19
On this page
- Regulatory response to COVID-19
- Regulating drugs and vaccines sold in Canada
- Monitoring SARS-CoV-2 variants
- Potential drugs and vaccines for COVID-19
- Clinical trials for drugs and vaccines
- Market authorization
- Special Access Program
- Addressing drug shortages
Regulatory response to COVID-19
The COVID-19 pandemic has created an unprecedented demand on Canada's health care system and has led to an urgent need for access to health products.
As part of the government's broad response to the pandemic, Health Canada introduced new innovative and agile regulatory measures. These measures expedite the regulatory review of COVID-19 health products without compromising safety, efficacy and quality standards.
These measures are helping to make health products needed for COVID-19, such as investigational drugs and vaccines, available to Canadians and health care workers.
We are also working with our international partners on a coordinated and well-aligned approach to this global pandemic. This ensures that our policies and regulatory approaches are aligned and that health products are safe, effective and quickly available to Canadians. Collaboration also helps advance the development of diagnostics, treatments and vaccines that will save lives and protect the health and safety of people everywhere.
Regulating drugs and vaccines sold in Canada
Drugs, including vaccines, are regulated under the Food and Drugs Act and Regulations. They must meet the regulatory requirements for safety, efficacy and quality before they can be sold in Canada. Health Canada's regulatory process involves:
- authorizing the use of a product in a clinical trial
- reviewing data and evidence to provide a product market authorization and
- monitoring and assessing the safety and effectiveness of a product once it is on the Canadian market
We have authorized certain products to treat COVID-19 and its symptoms.
On December 9, 2020, we authorized the first vaccine in Canada for the prevention of COVID-19.
Find out about COVID-19 vaccines that are authorized in Canada.
You can search the complete list of drugs and vaccines that have been authorized for treating and preventing COVID-19.
Monitoring SARS-CoV-2 variants
Genetic variations are common in viruses such as the SARS-CoV-2 that causes COVID-19. The federal government is closely monitoring the genetic variants of this virus to assess impacts on the COVID-19 pandemic in Canada. We evaluate new variants in collaboration with international experts to define key characteristics such as severity of disease, transmission, and impacts on vaccine or treatment effectiveness.
Health Canada is monitoring the emerging variants closely. We are working with manufacturers, international regulators, and the World Health Organization to determine if the new variants reduce the effectiveness of approved vaccines and treatments. Health Canada also requires manufacturers to consider the impacts of variants during product development, and evaluate the effectiveness of approved vaccines and therapeutics as new variants emerge. If an issue is identified, Health Canada will work quickly with the manufacturers and public health laboratories to respond and to keep everyone in Canada informed.
We have issued guidance documents for COVID-19 treatments and vaccines. Regulatory tools are in place to support the development and expedited regulatory review of new variant-specific vaccines and treatments if this becomes necessary. Health Canada is also working with international regulators to ensure a clear and consistent approach to vaccines targeting new variants. This approach is outlined in our international variant statements:
- Modified COVID-19 vaccines for variants to be fast-tracked
- ACCESS Consortium: Points to consider for strain changes in authorized COVID-19 vaccines in an ongoing SARS-CoV2 pandemic
Potential drugs and vaccines for COVID-19
There are many potential drugs being investigated in Canada and around the world for use against COVID-19. We are closely tracking all potential drugs and vaccines in development.
Potential COVID-19 drugs currently being investigated in Canadian clinical trials include:
- antiviral drugs
- monoclonal antibodies and other drugs that address inflammation
- convalescent plasma collected from patients who have recovered from COVID-19
- medical gases
You can search the complete list of applications received for COVID-19-related drugs and vaccines and their status.
Clinical trials for drugs and vaccines
Clinical trials are the most appropriate way for Canadians to access experimental drugs or vaccines that could help treat or prevent COVID-19. During a trial, companies or sponsors collect information on the risks and benefits of a drug or vaccine. Participants must give their informed consent in order to participate.
Sponsors must apply to conduct a clinical trial in Canada. The new Clinical Trials for Medical Devices and Drugs Relating to COVID-19 Regulations (the Regulations), published in the Canada Gazette II on March 2, 2022, came into effect on February 27, 2022, following the repeal of the Interim Order No. 2.The Regulations are a temporary measure. They will maintain the flexibilities and pathway set out by the interim order until the framework established through the Clinical Trials Modernization Initiative is in place. By reducing administrative burden, the Regulations will continue to:
- facilitate the authorization and implementation of COVID-19-related clinical trials
- uphold the health and safety requirements for trial participants and validity of trial data
In addition to the Regulations, Health Canada is working hard to expedite the authorization of trials for COVID-19. Applications are being reviewed faster than usual to speed up access without compromising patient safety. We are also encouraging companies, academic research centres and investigators who have products in development and pre-clinical data to contact us before they apply so we can advise them on the regulatory process.
See Health Canada's complete list of authorized clinical trials for drugs and vaccines for COVID-19. For a broader list all of authorized clinical trials, including those not related to COVID-19, please visit Health Canada's clinical trials database.
Health Canada reviews scientific evidence of a drug or vaccine, including results from clinical trials, to assess the product's safety, efficacy and quality before it can be sold in Canada. To facilitate earlier access to COVID-19 drugs or vaccines, Health Canada prioritized the review of these products while ensuring there is adequate evidence of safety, efficacy and quality to merit access to Canadians.
On September 16, 2020, the Minister of Health signed an interim order (ISAD IO) that introduced a temporary regulatory pathway. This helped expedite the authorization for COVID-19-related drugs and vaccines without compromising patient safety.
As of October 2020, Health Canada began receiving submissions for approval under the ISAD IO. The data provided in each submission was carefully reviewed to ensure that any new vaccine or treatment made available to Canadians is safe, effective and of high quality.
The ISAD IO expired on September 16, 2021. To ensure that COVID-19-related drugs authorized under the ISAD IO may continue to be imported and sold in Canada, we introduced transition measures to amend the Food and Drug Regulations. The amendments ensure that the review, authorization and oversight of COVID-19 drugs, including new drugs, can now be conducted under the Regulations.
The Guidance on modified requirements for drugs for use in relation to COVID-19 outlines the process for meeting the post-regulatory requirements for COVID-19 drugs.
See Health Canada's complete list of applications received for COVID-19-related drugs and vaccines and their status. See also the complete list of all drugs and vaccines that have been authorized for treating COVID-19.
Special Access Program
The most appropriate way to access unproven treatments is through clinical trials. However, the Special Access Program (SAP) is also available to health care professionals who are treating seriously ill patients where conventional therapies have failed, are unsuitable or are unavailable.
The SAP authorizes a manufacturer to sell a drug on a case-by-case basis for an individual who requires access to a product that cannot otherwise be sold or distributed in Canada. Recently, the regulations for the program were modernized to better facilitate access to drugs for Canadians, including treatments for COVID-19. These regulatory changes will:
- reduce the administrative burden on health care professionals requesting access to drugs that have been authorized through the SAP and meet certain conditions
- help to reduce delays in getting a drug to a practitioner to treat their patient in a medical emergency
To access products under the SAP, health care professionals must ask Health Canada for permission and companies must agree to provide the product. We will review the evidence on the drug's safety and efficacy for use in a medical emergency. We will consider each request separately.
For questions about SAP, please email us at email@example.com.
Addressing drug shortages
We are actively monitoring the impact of the COVID-19 pandemic on the supply of drugs in Canada. This includes identifying areas in Canada's supply chain where supply may be vulnerable and addressing those vulnerabilities before shortages develop.
We have also introduced regulatory measures to address drug shortages.
On March 30, 2020, an interim order (IO) to prevent or ease shortages of drugs, medical devices and foods for a special dietary purpose was introduced. Among other things, this IO allows companies with drug establishment licences to import foreign drugs that meet similar high quality and manufacturing standards as Canadian-approved drugs. See the list of drugs for exceptional importation and sale.
As well, on September 18, 2020, the Minister of Health approved an IO on preventing and alleviating drug shortages in relation to COVID-19. This IO provides more tools to urgently address drug shortages related to COVID-19 by authorizing the Minister of Health to:
- compel anyone (under certain conditions) who sells a drug to provide information about a shortage or potential shortage of that drug related to COVID-19
- impose or amend terms and conditions on certain drug authorizations for preventing or alleviating a drug shortage related to COVID-19
- Health product highlights 2021: Helping you maintain and improve your health
- Regulations amending certain regulations concerning drugs and medical devices (shortages): Notice
- Guidance for market authorization requirements for COVID-19 drugs
- Mid-year update: Health products approved in 2021
- Drug and medical device highlights 2020: Helping you maintain and improve your health
- Critical Drug Reserve during the COVID-19 pandemic
- Adverse Events Following Immunization Report
- Update on remdesivir: continued monitoring
- Notice for industry: Ensuring predictability for interim orders relating to COVID-19
- Guidance for market authorization requirements for COVID-19 vaccines
- Good manufacturing practices and COVID-19
- Drug establishment licences and COVID-19
- Changes to notification requirements for biologic drugs: Notice to industry
- Importing and exporting designated drugs
- International statement about confidence in vaccines (for the general public)
- Joint statement on clinical trial oversight in Canada
- Interim order respecting clinical trials for medical devices and drugs relating to COVID-19: notice
- COVID-19 for health professionals
- Notice: Expedited review of health product submissions and applications to address COVID-19
- Notice for industry: Mandatory reporting requirement during the COVID-19 pandemic
- Notice for hospitals: Mandatory reporting requirement during the COVID-19 pandemic
- The regulation of vaccines for human use in Canada
Report a problem or mistake on this page
- Date modified: